ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DARE
OPTH (46) ALLR (32) CTXR (40) BFRI (26) ⌘ Pro Terminal →

Dare Bioscience Inc. (DARE) — RQD Stock Rating Cockpit

$0.66 -6.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.65

Dare Bioscience Inc. (DARE) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $13.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DARE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Dare Bioscience Inc. (NASDAQ: DARE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.66 (-6.37% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #578 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DARE compare to OPTH and ALLR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, OPTH (Optimi Health Corp.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $13.8M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DARE?
▼

Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.65 (-1.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (6)SEC (11)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
$4 Bull$1 Base$0 Bear
📬 FREE DARE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DARE)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY DARE SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 71.3% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$0.75-8% Next Q
Q2 (-2Q)
41
Grade D$0.69-4.3% Next Q
Q3 (-1Q)
39
Grade E$0.66+0% Next Q
Current
36
Grade D-$0.66-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DARE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DARE currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.74) and Max Pain ($0.69) forces dealer call-delta covering toward $3.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DARE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DARE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
44.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$0.66H: $4
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on DARE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 71.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (55)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

11/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like DARE
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DARE)

  • ✓Walkthrough of DARE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DARE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.78%▲ RESISTANCE BREAKOUT
2026-11-03O $0.68H $0.70L $0.66C $0.66VOL 654.0K
RES: $0.53SUP: $0.62SMA50: $0.74SMA200: $1.57
$4.00$3.09$2.17$1.26$0.35RES $0.53SUP $0.62$0.662026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DARE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DARE Butterfly Map → + Track DARE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DARE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DARE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DARE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DARE)

Health Care Rank #578 of 1016 ⚔️ OPTH vs DARE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DARE vs. OPTH, ALLR, CTXR, BFRI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dare Bioscience Inc. (DARE) ranks #578 by composite RQD confidence (36/100, grade D-) and #862 by equity capitalization ($13.8M). Within this direct 5-issuer industry benchmark cohort, DARE leads on earnings valuation at N/A trailing P/E, while DARE leads on capital efficiency and profitability with -35.0% ROIC and 71.3% gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DARE at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DARE ACTIVE
Dare Bioscience Inc.
D- 36/100 — 71.3% -35.0% -6.37% $13.8M Benchmark Subject
OPTH
Optimi Health Corp.
D 46/100 — — — -7.05% $13.8M /opth-vs-dare →
ALLR
Allarity Therapeutics Inc.
E 32/100 — — -35.0% +12.33% $13.8M /allr-vs-dare →
CTXR
Citius Pharmaceuticals Inc.
D- 40/100 — — -35.0% +7.44% $14.4M /ctxr-vs-dare →
BFRI
Biofrontera Inc.
E 26/100 — — -35.0% -0.32% $13.0M /bfri-vs-dare →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001401914

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dare Bioscience Inc. (DARE) reported GAAP revenue of $1.0M (+10429.4% vs. FY2024 revenue of $9.8K , and -63.3% cumulative change since FY2023) , GAAP net income of -$13.4M, operating cash flow of -$9.9M, and free cash flow of -$10.3M (-309.6% YoY). On the balance sheet, DARE closed FY2025 with $32.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.0M -$13.4M -$9.9M -$10.3M $32.5M —
FY2024 (FY) 2024-12-31 $9.8K -$4.0M $5.5M $4.9M $22.1M —
FY2023 (FY) 2023-12-31 $2.8M -$30.2M -$38.9M -$38.9M — —

3. DARE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DARE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Dare Bioscience Inc. (NASDAQ: DARE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.66 (-6.37% 1D, market cap $13.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, DARE ranks #578 in composite RQD confidence.

How does DARE compare to OPTH and ALLR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DARE carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -35.0%. By comparison, OPTH (Optimi Health Corp.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $13.8M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, DARE leads on earnings multiple (N/A) while DARE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DARE?

Per DARE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401914), Dare Bioscience Inc. generated $1.0M in revenue (+10429.4% YoY), -$13.4M in net income, and -$10.3M in free cash flow against $32.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DARE trading relative to its 50-day, 200-day, and 52-week technical levels?

DARE last traded at $0.66 (-6.37% on volume of 206,418 shares), positioning the stock -10.81% below its 50-day simple moving average ($0.74) and -57.96% below its 200-day simple moving average ($1.57). Across its 52-week range of $0.63 to $3.78, DARE sits at the 1.0% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($1.00 to $0.74).

Direct Sub-Reports: DARE RQD Cockpit DARE 12M Forecast DARE Earnings & Move DARE Dividends & DRIP DARE Insiders & 13F DARE Whale Options DARE Profit Sankey DARE News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

DARE — Dare Bioscience Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Dare Bioscience Inc. (DARE) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.66 (-6.37% 1D, market capitalization $13.8M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 71.3%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Dare Bioscience Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Specific products, customers, and revenue model details are — The reported gross margin of 71.3% indicates the company retains a large share of revenue after direct costs, while reported operating margin of -60% shows operating expenses exceed revenue. Revenue in the most recent reported year was $1.0M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Dare Bioscience Inc. (DARE) reported $1.0M in annual revenue (up from $9.8K in FY2024, +10429.4% YoY) and -$13.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.8M revenue, -$30.2M net income) through FY2025, DARE scaled operating cash flow to -$9.9M and free cash flow to -$10.3M, backed by $32.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.63 – $3.78 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain: NONE; butterfly links: none; proprietary signals: none. No upstream or downstream dependencies, sector correlations beyond the stated Health Care classification, or second-order bottlenecks are identified in the source data. Investors should note that the absence of mapped links means this dataset cannot identify ripple effects from partners, suppliers, or customers.

  • Key Question #1: Can DARE sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.0M and free cash flow of -$10.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is DARE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DARE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dare Bioscience Inc. (DARE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DARE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DARE Bull vs. Bear Conversation Board — What's Your Call at $0.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DARE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DARE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.90 (+28.6%)
📌 Pinned Debate

Balance sheet is the strongest RQD pillar at 11/20, with reported cash of $24.7M at FY 2025 and a Debt/Equity of 0.5.

Picked up a starter position in DARE in my $100K Virtual Cash book at $0.70. Balance sheet is the strongest RQD pillar at 11/20, with reported cash of $24.7M at FY 2025 and a Debt/Equity of 0.5.. Trading inside a $0.63–$3.78 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@CashFlowKing Agree on the RQD 36/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.70 and keeping dry powder in case we test $0.65.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.56 (-20.0%)
Spot @ $0.70

Operating margin of -60%, ROIC of -35%, and a FCF yield of 0% show the company is not converting its capital base into cash returns.

Operating margin of -60%, ROIC of -35%, and a FCF yield of 0% show the company is not converting its capital base into cash returns.. Look at the math on DARE: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.62 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%